Brief: 4DMT Reports Long-Term Phase 1/2 Data Showing Durable Multi-Year Benefit of 4D-150 in Wet AMD

4D Molecular Therapeutics

06/11/2025 11:59

Nov 6 (Reuters) - 4D Molecular Therapeutics Inc FDMT.O:

4DMT ANNOUNCES POSITIVE LONG-TERM DATA FROM PHASE 1/2 PRISM CLINICAL TRIAL IN WET AMD SUPPORTING 4D-150’S POTENTIAL AS A BACKBONE THERAPY WITH CONSISTENT AND DURABLE BENEFIT OVER MULTIPLE YEARS

4D MOLECULAR THERAPEUTICS INC - 4D-150 WELL TOLERATED WITH NO NEW SAFETY ISSUES

Source text: ID:nGNXbrcZZq

Further company coverage: FDMT.O

 ((Reuters.Briefs@thomsonreuters.com;))